Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | SGC0946 |
Synonyms | |
Therapy Description |
SGC0946 inhibits DOT1L, resulting in reduced viability of leukemia cells with MLL fusions (PMID: 23250418, PMID: 28209620). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
SGC0946 | DOT1L Inhibitor 3 | SGC0946 inhibits DOT1L, resulting in reduced viability of leukemia cells with MLL fusions (PMID: 23250418, PMID: 28209620). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|